| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Repligen Corporation (NASDAQ:RGEN) agreed to acquire Sweden-based privately-held Metenova.
Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023.
The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.
Metenova is expected to contribute approximately $5 million in revenue to Repligen in Q4 of 2023 and $25 million-$27 million in 2024, with 20%-25% revenue growth in 2025 forward.
The acquisition is anticipated to be accretive to Repligen's adjusted gross and operating margins in 2024 and to be accretive to adjusted EPS in 2025.
The transaction is expected to be completed in the coming weeks.
According to William Blair, this agreement significantly expands Repligen's market reach by granting the company access to the lucrative $1 billion mixing sector and enhancing its capabilities in fluid management.
Repligen has consistently demonstrated a strong history of strategic acquisitions to bolster its product portfolio, and Metenova's addition follows recent fluid management deals like FlexBiosys, ARTeSYN, Bioflex, EMT, and NMS.
These additions complement an existing $50 million fluid management division.
This move aligns with the company's strategic focus on vertical integration and enhanced supply chain control, as highlighted during last year's investor day.
While Metenova does have some shared end-user customers, its primary sales channel involves collaborating with engineering firms overseeing new construction projects.
Repligen aims to capitalize on its existing end-user relationships to gain a competitive edge, particularly against rivals like Merck KGaA (OTC: MKGAF) (OTC: MKKGY), especially in the stainless steel segment.
William Blair reaffirms the Outperform rating by highlighting Repligen's long-term positioning and opportunity in the bioprocessing capacity.
Price Action: RGEN shares are down 0.34% at $158.45 on the last check Tuesday.
